Navigation Links
Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
Date:2/14/2008

PARIS, February 14 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the Chicago Athenaeum Museum of Architecture and Design has awarded a 2007 GOOD DESIGN(TM) Award for the new SoloSTAR(R) disposable insulin injection pen for people with type 1 and type 2 diabetes.

"LANTUS(R) SoloSTAR(R) and APIDRA(R) SoloSTAR(R), the results of over four years of intensive development, have been designed in dialogue with patients, nurses and doctors and meet the high standards of the industry," said Paul Jansen, Global Head Medical Devices, sanofi-aventis.

"We are proud to receive this prestigious GOOD DESIGN Award for SoloSTAR(R) as a recognition of our strong commitment to people with diabetes", Gilles Lhernould, Senior Vice President Industrial Affairs sanofi-aventis added.

For some people with diabetes, self-injection can be a barrier to acceptance of insulin therapy. "SoloSTAR(R) is a marriage of sleek, handsome design styling with easy, but advanced sophisticated technology for dispensing insulin to people with diabetes," says Christian K. Narkiewicz-Laine, President Chicago Athenaeum Museum of Architecture and Design. "SoloSTAR(R) represents a design for social good and for humanitarian concerns".

When choosing a specific insulin pen for an individual patient, clinicians consider the patient's insulin regimen, lifestyle, and other factors that may affect the ability to use a particular device, such as manual dexterity and visual acuity. Therefore certain characteristics of a given insulin pen may make it preferable for patients. The outstanding design of SoloSTAR(R) using breakthrough technology contributes to making this patients' and clinicians' choice easier.

SoloSTAR(R) provides a delivery option that may be more acceptable and more convenient to use in comparison with other delivery systems, thus may promote patient compliance, which could help achieve and maintain glycemic control.

A recent survey of LANTUS(
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Smart insulin nanostructures pass feasibility test, UT study reports
5. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
6. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
7. Novel Alternative Approach to Inhibiting Insulin Growth Factor (IGF) May Provide New Treatment for Breast Cancer and Other Cancers
8. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
9. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... Switzerland , April 16, 2015 ... of Debiopharm Group ™ , a Swiss-based global ... unmet medical needs as well as companion ... the investigational compounds Debio 1143 (SMAC mimetic) and ... at the 2015 Annual meeting of the ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Fairleigh ... Joseph V. Gulfo to become the Executive Director ... Simultaneously, FDU announced the kick-off of the Initiative ... spearheaded by Dr. Gulfo, under the Rothman Institute ... of Business) and in collaboration with FDU’s School ...
(Date:4/16/2015)... Dana-Farber Cancer Institute and its ... Bioscience, Inc. today announced the successful completion of ... clinic ready, Next Generation Sequencing (NGS) assay for ... the first to demonstrate the successful sequencing of ... blinded plasma samples and highlights the ability to ...
Breaking Biology Technology:Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... Double 2009 Grant Awards to Nearly $4 Million , ... Lustgarten Foundation, the nation,s largest private supporter of pancreatic cancer ... $1.6 million awarded to six leading research centers for early ... deadliest cancers. , , Lustgarten is expected to ...
... , VIENNA, Austria, June 23 ... 2009 Venture Capital & Private Equity Award,competition, hosted by the ... association between the,German venture fund and the Austrian biotechnology company ... GSK Biologicals. , Last Tuesday MIG ...
... Calif., June 22 ForteBio(R), Inc., a leading ... of biotherapeutic and pharmaceutical products, announced today that ... RED384 for protein, peptide, small molecule and fragment ... antibody assays. The new instruments will debut this ...
Cached Biology Technology:The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384 2ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384 3
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... "red light green light," winners are able to stop, ... comrades. New research reveals that a similar race goes ... big winner. , "The research provides new insights into ... impulsivity of people with attention deficit and hyperactivity disorder," ...
... on how erectile dysfunction (ED) interacts with diabetes. The ... the two disorders, and may lead to improved efficacy ... Nitric Oxide Triggers Erectile Dysfunction in Diabetes," was conducted ... Patel, Departments of Cellular and Integrative Physiology; and Keshore ...
... University of Missouri-Columbia, recently found fossil evidence in seven ... that showed people were eating domesticated chili peppers as ... one of the oldest domesticated food sources in the ... 15 edition of the journal Science. , "Before our ...
Cached Biology News:Racing neurons control whether we stop or go 2Racing neurons control whether we stop or go 3Erectile dysfunction in diabetes is due to selective defect in the brain 2Erectile dysfunction in diabetes is due to selective defect in the brain 3Researchers find 6,000-year-old fossil evidence 2